47 results
6-K
TAK
Takeda Pharmaceutical Co
1 Oct 21
Current report (foreign)
6:03am
Number
Statement regarding Moderna COVID-19 Vaccine Recall Investigation Report – October 2021
SIGNATURES
Pursuant to the requirements of the Securities …
STATEMENT REGARDING MODERNA COVID-19 VACCINE RECALL INVESTIGATION REPORT – OCTOBER 2021
Osaka, Japan, October 1, 2021—Takeda and Moderna today published
6-K
TAK
Takeda Pharmaceutical Co
22 Mar 22
Current report (foreign)
6:13am
be approved in its present form. The PAS was submitted in August 2021 to address the potential for rubber particulate formation that led to a local U.S. recall … have described over the past year. Those challenges are unrelated to the PAS and the recall. It is important to underscore that all product released
6-K
TAK
Takeda Pharmaceutical Co
7 Sep 21
Current report (foreign)
6:02am
a second dose vaccination on August 11 from lot 3004734 – one of the three lots included in the recall announced last week and which lot has no product … were included in the suspension by MHLW out of an abundance of caution. Takeda initiated the recall of the three suspended lots on September 2
6-K
TAK
Takeda Pharmaceutical Co
4 Oct 22
Current report (foreign)
6:06am
formation issue, which led to the U.S. recall of NATPARA in 20192. Despite these efforts, Takeda has unfortunately determined there is not a sustainable … ® for use in Europe and all other markets, in which the medication is commercially available.
2 “Takeda Issues US Recall of NATPARA® (parathyroid
6-K
TAK
Takeda Pharmaceutical Co
31 Oct 19
Current report (foreign)
6:06am
, and the NATPARA recall in the U.S.*2, partially offset by upwardly revised assumptions for products such as ENTYVIO, TAKECAB and VYVANSE.
Core … its full-year profit and margin guidance with business momentum more than offsetting the recall of NATPARA in the U.S.
Previous Guidance
(July 31
6-K
c7s527u9d1 0sm
29 Nov 19
Current report (foreign)
6:03am
6-K
xfzkhgxbx9h7d
1 Sep 21
Current report (foreign)
8:01am
6-K
i6r2cjjmjumj4v63vnl
31 Oct 19
Current report (foreign)
6:15am
6-K
lji2ze
30 Nov 20
Current report (foreign)
6:18am
6-K
co90nf9
4 Feb 21
Current report (foreign)
6:05am
6-K
dls2qy4ajhxlpptiylga
31 Jul 20
Current report (foreign)
8:45am
20FR12B/A
EX-10.1
68lub1
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
20FR12B
EX-10.1
wrri9e9goc
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
DRS/A
EX-10.1
x36f n9b0ac6t9v
16 Nov 18
Draft registration statement (amended)
12:00am
6-K
w0ixqm
11 May 21
Current report (foreign)
6:08am
6-K
tmtktja49
12 Aug 20
Current report (foreign)
6:10am
6-K
lero 87onn
10 Nov 20
Current report (foreign)
6:01am
6-K
emcfkkh q71im2o
12 Feb 21
Current report (foreign)
6:04am
6-K
877z4vk 09bj
28 Oct 21
Current report (foreign)
6:12am